SCHEMBL2677876

SCHEMBL2677876

CCN1CCN(c2ccc(C(=O)Nc3n[nH]c4c3CN(S(=O)(=O)c3cc(F)cc(F)c3)CC4(C)C)c(N)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 5/20 0.50
ALK Q9UM73 3/20 0.47
INSR P06213 2/20 0.47
NTRK1 P04629 10/20 0.44
NTRK3 Q16288 5/20 0.44
NTRK2 Q16620 4/20 0.44
CCNA2 P20248 3/20 0.41
CDK2 P24941 3/20 0.41
CCNA1 P78396 3/20 0.41
PRKCB P05771 2/20 0.39
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37
CCNE1 P24864 1/20 0.37
GSK3B P49841 1/20 0.37
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
PLK4 O00444 1/20 0.37
DAPK3 O43293 1/20 0.37
PRKCG P05129 1/20 0.37
ROS1 P08922 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2452594 0.93 IGF1R (0.59) IGF1RALKINSRNTRK1NTRK3
SCHEMBL2677873 0.92 IGF1R (0.49) IGF1RALKINSRNTRK1NTRK3
SCHEMBL2678535 0.91 NTRK1 (0.52) IGF1RALKINSRNTRK1NTRK3
SCHEMBL1885378 0.87 INSR (0.52) IGF1RALKINSRNTRK1NTRK3
SCHEMBL2678944 0.87 IGF1R (0.52) IGF1RALKINSRNTRK1NTRK3
SCHEMBL2678321 0.87 IGF1R (0.67) IGF1RALKINSRNTRK1NTRK3
SCHEMBL2679436 0.86 IGF1R (0.52) IGF1RALKINSRNTRK1NTRK3
SCHEMBL1888222 0.85 IGF1R (0.52) IGF1RALKINSRNTRK1NTRK3
SCHEMBL1894137 0.85 IGF1R (0.60) IGF1RALKINSRNTRK1NTRK3
SCHEMBL1894098 0.85 IGF1R (0.59) IGF1RALKINSRNTRK1NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 US disclosed
EP-1968976-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-09-17 EP disclosed
WO-2007068619-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885ALK 517/4885INSR 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.